Evidence map›Paper›PMID 41218108›Full record

ArticleAntimicrobial agents and chemotherapy2025

Inhibitors of the 20S proteasome β5 subunit as potent and selective agents against

Yukiko Miyamoto, Brianna M Hurysz, Pavla Fajtova, Peter Eckmann, Mateus Sá Magalhães Serafim, Thales Kronenberger, Momen Al-Hindy, Patrick M Dekker, Elmer Maurits, Herman S Overkleeft and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Antimicrobial agents and chemotherapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Yukiko Miyamoto *Department of Medicine, University of California San Diego, La Jolla, California, USA.
Brianna M Hurysz *Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, California, USA.
Pavla FajtovaSkaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, California, USA.
Peter EckmannDepartment of Computer Science and Engineering, University of California San Diego, La Jolla, California, USA.
Mateus Sá Magalhães SerafimSkaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, California, USA.
Thales KronenbergerInstitut für Medizinische Mikrobiologie und Hygiene, Partner-site Tübingen, German Center for Infection Research (DZIF), Tübingen, Germany.
Momen Al-HindyScripps Institution of Oceanography, University of California San Diego, La Jolla, California, USA.
Patrick M DekkerGorlaeus Laboratories, Leiden Institute of Chemistry, Leiden, the Netherlands.
Elmer MauritsGorlaeus Laboratories, Leiden Institute of Chemistry, Leiden, the Netherlands.
Herman S OverkleeftGorlaeus Laboratories, Leiden Institute of Chemistry, Leiden, the Netherlands.
B Mikael BergdahlDepartment of Chemistry and Biochemistry, San Diego State University, San Diego, California, USA.
Jehad AlmalitiScripps Institution of Oceanography, University of California San Diego, La Jolla, California, USA.
William H GerwickSkaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, California, USA.
Anthony J O'DonoghueSkaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, California, USA.
Lars EckmannDepartment of Medicine, University of California San Diego, La Jolla, California, USA.ORCID 0000-0002-7987-8742

Funding

San Diego Digestive Diseases Research CenterP30DK120515 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Bernd G. Schnabl · 2019 to 2026
$10.8M
Discovery of Anticancer Drugs from CyanophytesR01CA100851 · NCI · HENRY FORD HEALTH SYSTEM · PI VALERIOTE, FREDERICK AUGUSTUS · 2004 to 2013
$3.8M
Proteasome inhibitors against mucosal protozoan pathogensR01AI158612 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ECKMANN, LARS, O'DONOGHUE, ANTHONY JOHN · 2021 to 2025
$3.2M
Cellular and Molecular Pharmacology Training ProgramT32GM153123 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI JOAN HELLER BROWN, Tracy M Handel · 2024 to 2026
$1.3M
The catalytic core of the proteasome as a drug target to treat Human African TrypanosomiasisR21AI171824 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI CAFFREY, CONOR, O'DONOGHUE, ANTHONY JOHN · 2022 to 2023
$435k
Selective proteasome inhibitors for trichomoniasisR21AI146387 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ECKMANN, LARS, O'DONOGHUE, ANTHONY JOHN · 2019 to 2020
$433k
Exploring the proteasome as a new drug target to treat schistosomiasisR21AI133393 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI O'DONOGHUE, ANTHONY JOHN · 2017 to 2018
$426k
NCI NIH HHS R01 CA100851NIAID NIH HHS R01 AI158612NIAID NIH HHS R21 AI133393NIAID NIH HHS R21 AI146387NIAID NIH HHS R21 AI171824NIDDK NIH HHS P30 DK120515NIGMS NIH HHS T32 GM153123NIH HHS AI133393NIH HHS AI146387NIH HHS AI158612NIH HHS AI171824NIH HHS CA100851NIH HHS DK120515NIH HHS GM153123
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Antiprotozoal AgentsProteasome Endopeptidase ComplexProteasome InhibitorsTrichomonas vaginalisHumansMetronidazoleMolecular Docking SimulationAntiprotozoal AgentsMetronidazoleProteasome Endopeptidase ComplexProteasome Inhibitorsantimicrobialsdocking simulationsproteasome subunitstrichomoniasis

Identifiers

PMID41218108
PMCPMC12691669

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.